Screening for Masked Hypertension With Smart Wearable Devices (SMART)

Masked Hypertension Clinical Trial

— SMART  

Official title:

Screening for Masked Hypertension in Young and Middle-aged Adults With Smart Wearable Devices (SMART)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05409898
• Other study ID #: 2022PHB108
• Status: Not yet recruiting
• Start date: July 2022
• Est. completion date: July 2024

Study information

• Verified date: June 2022
• Source: Peking University People's Hospital
• Contact: Jing Liu, MD
• Phone: 01088325457
• Email: heartcenter[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In recent years, a large number of consumer-grade and Smart Wearable Devices (SWD) such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially masked hypertension, in young and middle-aged people. "Screening for masked hypertension in young and middle-aged adults with smart wearable devices" （SMART）aims to screen for masked hypertension using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure (BP) in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is >= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

Description:

Masked hypertension (MH) is defined as elevated ambulatory or home blood pressure (BP), but normal office BP, often complicated with severe cardiovascular and renal damage. MH is easily missed and needs to be identified by "out-of-office" BP measurements such as ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM). However, in clinical practice, ABPM has poor accessibility, high cost, and requires appointments, making it difficult to meet the demand; HBPM has better accessibility, but low utilization and irregular use are more prominent. In addition, these devices interfere with sleep and activity when measuring BP, so their clinical application is somewhat limited. Smart wearable devices (SWD) can sense and record various physiological parameters of human body, and analyze the health status of individuals with the support of software algorithms. In recent years, a large number of consumer-grade and SWD such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially MH, in young and middle-aged people. "Screening for masked hypertension in young and middle-aged adults with smart wearable devices" （SMART） aims to screen for MH using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is >= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: July 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. 18-50 years of age, male or female

2. No clear previous history of hypertension and other cardiovascular diseases

3. Signed informed consent form

Exclusion Criteria:

1. Patients with established hypertension

2. History of severe heart, liver, or kidney disease

3. Inability to cooperate in completing the study

Related Conditions & MeSH terms

• Hypertension
• Masked Hypertension

Intervention

Device:
• smart wearable device
screening masked hypertension with smart wearable devices

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Jing Liu	HUAWEI

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of masked hypertension	Average systolic/diastolic BP during 7 days of the observation period will be calculated.; Office BP should be measured when the average BP is =135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is < 140/90 mmHg at visit, "Masked Hypertension" will be diagnosed.; The prevalence of masked hypertension will be calculated as the following: number of masked hypertension/number of subjects included.	7 days
Secondary	Prevalence of hypertension	Average systolic/diastolic BP during 7 days of the observation period will be calculated.; Office BP should be measured when the average BP is =135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is =140/90 mmHg at visit, the diagnosis will be "Hypertension".; The prevalence of hypertension will be calculated as the following: number of hypertension/number of subjects included.	7 days